Metformin increases sensitivity of osteosarcoma stem cells to cisplatin by inhibiting expression of PKM2

Shang,Depeng; Wu,Ju; Guo,Lianyi; Xu,Yanju; Liu,Lezi; Lu,Jianmin

doi:10.3892/ijo.2017.3950

Metformin increases sensitivity of osteosarcoma stem cells to cisplatin by inhibiting expression of PKM2

Authors:
- Depeng Shang
- Ju Wu
- Lianyi Guo
- Yanju Xu
- Lezi Liu
- Jianmin Lu
View Affiliations

Affiliations: Department of Orthopedics, Zhongshan Hospital Affiliated of Dalian University, Dalian, Liaoning 116001, P.R. China, Department of General Surgery, Zhongshan Hospital Affiliated of Dalian University, Dalian, Liaoning 116001, P.R. China, Department of Gastroenterology, The First Affiliated Hospital of Jinzhou Medical University, Jinzhou, Liaoning 121001, P.R. China
Published online on: April 5, 2017 https://doi.org/10.3892/ijo.2017.3950
Pages: 1848-1856

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Multiple drug resistance is reported to be a major obstacle in treatment of osteosarcoma (OS). Research has demonstrated that small subsets of cells called cancer stem cells (CSCs) are responsible for multiple drug resistance. CSCs are potential targets for reversing chemoresistance. In the present study, we compared cisplatin sensitivity between OS stem cells and OS non-stem cells. We confirmed that OS stem cells showed significant cisplatin-resistance compared with the OS non-CSCs. Mechanically, we proved that overexpression of the pyruvate kinase isoenzyme M2 (PKM2) was responsible for the resistance to cisplatin in OS stem cells. As a potential strategy, we found that co-treatment with metformin significantly decreased the half maximal inhibitory concentration (IC50) of cisplatin to HOS OS stem cells by downregulating the expression of PKM2. PKM2 downregulation resulted in, metformin inhibited glucose uptake, lactate production and ATP production in HOS CSCs. Therefore, metformin impaired the resistance of HOS CSCs to cisplatin and promoted cisplatin-induced apoptosis. In addition, antitumor effects of other chemotherapeutic drugs such as doxorubicin and 5-fluorouracil were proved to be enhanced by metformin on OS stem cells.

View Figures

View References

1	Siegel R, Naishadham D and Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 63:11–30. 2013. View Article : Google Scholar : PubMed/NCBI
2	Huang J, Liu K, Song D, Ding M, Wang J, Jin Q and Ni J: Krüppel-like factor 4 promotes high-mobility group box 1-induced chemotherapy resistance in osteosarcoma cells. Cancer Sci. 107:242–249. 2016. View Article : Google Scholar :
3	Sun Y, He N, Dong Y and Jiang C: MiR-24-BIM-Smac/DIABLO axis controls the sensitivity to doxorubicin treatment in osteosarcoma. Sci Rep. 6:342382016. View Article : Google Scholar : PubMed/NCBI
4	Shackleton M, Quintana E, Fearon ER and Morrison SJ: Heterogeneity in cancer: Cancer stem cells versus clonal evolution. Cell. 138:822–829. 2009. View Article : Google Scholar : PubMed/NCBI
5	Clarke MF and Fuller M: Stem cells and cancer: Two faces of eve. Cell. 124:1111–1115. 2006. View Article : Google Scholar : PubMed/NCBI
6	Martins-Neves SR, Paiva-Oliveira DI, Wijers-Koster PM, Abrunhosa AJ, Fontes-Ribeiro C, Bovée JV, Cleton-Jansen AM and Gomes CM: Chemotherapy induces stemness in osteosarcoma cells through activation of Wnt/β-catenin signaling. Cancer Lett. 370:286–295. 2016. View Article : Google Scholar
7	Yang J, Guo W, Wang L, Yu L, Mei H, Fang S, Ji P, Liu Y, Liu G and Song Q: Cisplatin-resistant osteosarcoma cells possess cancer stem cell properties in a mouse model. Oncol Lett. 12:2599–2605. 2016.PubMed/NCBI
8	Gonçalves C, Martins-Neves SR, Paiva-Oliveira D, Oliveira VE, Fontes-Ribeiro C and Gomes CM: Sensitizing osteosarcoma stem cells to doxorubicin-induced apoptosis through retention of doxorubicin and modulation of apoptotic-related proteins. Life Sci. 130:47–56. 2015. View Article : Google Scholar : PubMed/NCBI
9	Ni M, Xiong M, Zhang X, Cai G, Chen H, Zeng Q and Yu Z: Poly(lactic-co-glycolic acid) nanoparticles conjugated with CD133 aptamers for targeted salinomycin delivery to CD133⁺ osteosarcoma cancer stem cells. Int J Nanomedicine. 10:2537–2554. 2015. View Article : Google Scholar :
10	Feng X, Jiang J, Shi S, Xie H, Zhou L and Zheng S: Knockdown of miR-25 increases the sensitivity of liver cancer stem cells to TRAIL-induced apoptosis via PTEN/PI3K/Akt/Bad signaling pathway. Int J Oncol. 49:2600–2610. 2016.PubMed/NCBI
11	Chen Y, Zhang F, Tsai Y, Yang X, Yang L, Duan S, Wang X, Keng P and Lee SO: IL-6 signaling promotes DNA repair and prevents apoptosis in CD133⁺ stem-like cells of lung cancer after radiation. Radiat Oncol. 10:2272015. View Article : Google Scholar
12	Adler AI, Shaw EJ, Stokes T and Ruiz F; Guideline Development Group: Newer agents for blood glucose control in type 2 diabetes: Summary of NICE guidance. BMJ. 338:b16682009. View Article : Google Scholar : PubMed/NCBI
13	Tseng CH: Metformin reduces thyroid cancer risk in Taiwanese patients with type 2 diabetes. PLoS One. 9:e1098522014. View Article : Google Scholar : PubMed/NCBI
14	Dowling RJ, Niraula S, Stambolic V and Goodwin PJ: Metformin in cancer: Translational challenges. J Mol Endocrinol. 48:R31–R43. 2012. View Article : Google Scholar : PubMed/NCBI
15	Zhao W, Zhang X, Liu J, Sun B, Tang H and Zhang H: miR-27a-mediated antiproliferative effects of metformin on the breast cancer cell line MCF-7. Oncol Rep. 36:3691–3699. 2016.PubMed/NCBI
16	Franciosi M, Lucisano G, Lapice E, Strippoli GF, Pellegrini F and Nicolucci A: Metformin therapy and risk of cancer in patients with type 2 diabetes: Systematic review. PLoS One. 8:e715832013. View Article : Google Scholar : PubMed/NCBI
17	El-Mir MY, Nogueira V, Fontaine E, Avéret N, Rigoulet M and Leverve X: Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 275:223–228. 2000. View Article : Google Scholar : PubMed/NCBI
18	Silvestri A, Palumbo F, Rasi I, Posca D, Pavlidou T, Paoluzi S, Castagnoli L and Cesareni G: Metformin induces apoptosis and downregulates pyruvate kinase M2 in breast cancer cells only when grown in nutrient-poor conditions. PLoS One. 10:e01362502015. View Article : Google Scholar : PubMed/NCBI
19	Yang W and Lu Z: Regulation and function of pyruvate kinase M2 in cancer. Cancer Lett. 339:153–158. 2013. View Article : Google Scholar : PubMed/NCBI
20	He Y, Wang Y, Liu H, Xu X, He S, Tang J, Huang Y, Miao X, Wu Y, Wang Q, et al: Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance. Leuk Res. 39:1428–1436. 2015. View Article : Google Scholar : PubMed/NCBI
21	Dayton TL, Jacks T and Vander Heiden MG: PKM2, cancer metabolism, and the road ahead. EMBO Rep. 17:1721–1730. 2016. View Article : Google Scholar : PubMed/NCBI
22	Garber K: Energy deregulation: Licensing tumors to grow. Science. 312:1158–1159. 2006. View Article : Google Scholar : PubMed/NCBI
23	Zhou Y, Tozzi F, Chen J, Fan F, Xia L, Wang J, Gao G, Zhang A, Xia X, Brasher H, et al: Intracellular ATP levels are a pivotal determinant of chemoresistance in colon cancer cells. Cancer Res. 72:304–314. 2012. View Article : Google Scholar
24	Ren XF, Mu LP, Jiang YS, Wang L and Ma JF: LY2109761 inhibits metastasis and enhances chemosensitivity in osteosarcoma MG-63 cells. Eur Rev Med Pharmacol Sci. 19:1182–1190. 2015.PubMed/NCBI
25	Yang Q, Zhang S, Kang M, Dong R and Zhao J: Synergistic growth inhibition by sorafenib and cisplatin in human osteosarcoma cells. Oncol Rep. 33:2537–2544. 2015.PubMed/NCBI
26	Davis W Jr, Ronai Z and Tew KD: Cellular thiols and reactive oxygen species in drug-induced apoptosis. J Pharmacol Exp Ther. 296:1–6. 2001.
27	Casares C, Ramírez-Camacho R, Trinidad A, Roldán A, Jorge E and García-Berrocal JR: Reactive oxygen species in apoptosis induced by cisplatin: Review of physiopathological mechanisms in animal models. Eur Arch Otorhinolaryngol. 269:2455–2459. 2012. View Article : Google Scholar : PubMed/NCBI
28	Gao JZ, Chen FH, Wang L, Wei H and Meng SL: YM155 inhibits tumor growth and enhances chemosensitivity to cisplatin in osteosarcoma. Eur Rev Med Pharmacol Sci. 19:2062–2069. 2015.PubMed/NCBI
29	Liu J, Tang Q, Li S and Yang X: Inhibition of HAX-1 by miR-125a reverses cisplatin resistance in laryngeal cancer stem cells. Oncotarget. 7:86446–86456. 2016.PubMed/NCBI
30	Abarrategi A, Tornin J, Martinez-Cruzado L, Hamilton A, Martinez-Campos E, Rodrigo JP, González MV, Baldini N, Garcia-Castro J and Rodriguez R: Osteosarcoma: Cells-of-origin, cancer stem cells, and targeted therapies. Stem Cells Int. 2016:36317642016. View Article : Google Scholar : PubMed/NCBI
31	Li Z, Yang P and Li Z: The multifaceted regulation and functions of PKM2 in tumor progression. Biochim Biophys Acta. 1846:285–296. 2014.PubMed/NCBI
32	He J, Xie G, Tong J, Peng Y, Huang H, Li J, Wang N and Liang H: Overexpression of microRNA-122 re-sensitizes 5-FU-resistant colon cancer cells to 5-FU through the inhibition of PKM2 in vitro and in vivo. Cell Biochem Biophys. 70:1343–1350. 2014. View Article : Google Scholar : PubMed/NCBI
33	He Y, Wang Y, Liu H, Xu X, He S, Tang J, Huang Y, Miao X, Wu Y, Wang Q, et al: Pyruvate kinase isoform M2 (PKM2) participates in multiple myeloma cell proliferation, adhesion and chemoresistance. Leuk Res. 39:1428–1436. 2015. View Article : Google Scholar : PubMed/NCBI
34	Chen G, Feng W, Zhang S, Bian K, Yang Y, Fang C, Chen M, Yang J and Zou X: Metformin inhibits gastric cancer via the inhibition of HIF1α/PKM2 signaling. Am J Cancer Res. 5:1423–1434. 2015.
35	Longley DB and Johnston PG: Molecular mechanisms of drug resistance. J Pathol. 205:275–292. 2005. View Article : Google Scholar : PubMed/NCBI